Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Wild

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
The Prostate|December 12, 2023
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancerDavid Moon, J Spencer Hauck, Xue Jiang, et al.
Journal of Clinical Lipidology|June 1, 2024
Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid AssociationAnandita Agarwala, Dave L Dixon, Eugenia Gianos, et al.
Molecular Cancer Therapeutics|October 7, 2010
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancerElizabeth Buck, Prafulla C Gokhale, Susan Koujak, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2008
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitorFeng Roger Luo, Yu Chen Barrett, Zheng Yang, et al.
NPJ Precision Oncology|November 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scoreChristoph Arolt, Andreas H Scheel, Margaret Dugan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 20, 2023
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLCChristoph Arolt, Margaret Dugan, Robert Wild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft modelFeng R Luo, Zheng Yang, Huijin Dong, et al.
Journal of Natural Products|June 28, 2003
Cytotoxic flavone analogues of vitexicarpin, a constituent of the leaves of Vitex negundoFredyc Díaz, Daniel Chávez, Dongho Lee, et al.
Cancer Letters|July 4, 2024
A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell deathMichael M Allevato, Sally Trinh, Keiichi Koshizuka, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 13, 2023
Associations of dietary cholesterol and fat, blood lipids, and risk for dementia in older women vary by APOE genotypeMichelle M Dunk, Jie Li, Simin Liu, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
The Prostate|December 12, 2023
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancerDavid Moon, J Spencer Hauck, Xue Jiang, et al.
Journal of Clinical Lipidology|June 1, 2024
Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid AssociationAnandita Agarwala, Dave L Dixon, Eugenia Gianos, et al.
Molecular Cancer Therapeutics|October 7, 2010
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancerElizabeth Buck, Prafulla C Gokhale, Susan Koujak, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2008
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitorFeng Roger Luo, Yu Chen Barrett, Zheng Yang, et al.
NPJ Precision Oncology|November 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scoreChristoph Arolt, Andreas H Scheel, Margaret Dugan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 20, 2023
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLCChristoph Arolt, Margaret Dugan, Robert Wild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft modelFeng R Luo, Zheng Yang, Huijin Dong, et al.
Journal of Natural Products|June 28, 2003
Cytotoxic flavone analogues of vitexicarpin, a constituent of the leaves of Vitex negundoFredyc Díaz, Daniel Chávez, Dongho Lee, et al.
Cancer Letters|July 4, 2024
A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell deathMichael M Allevato, Sally Trinh, Keiichi Koshizuka, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 13, 2023
Associations of dietary cholesterol and fat, blood lipids, and risk for dementia in older women vary by APOE genotypeMichelle M Dunk, Jie Li, Simin Liu, et al.
Pageof 7